Search results
Results From The WOW.Com Content Network
GoodRx released a list of 19 of the most influential drugs and vaccines approved by the FDA in 2024 to treat a variety of conditions. These medications are “slated to make a big clinical impact ...
In most cases, generic products become available after the patent protections afforded to the drug's original developer expire. Once generic drugs enter the market, competition often leads to substantially lower prices for both the original brand-name product and its generic equivalents. In most countries, patents give 20 years of protection.
New year, same old questions of access. As exciting as the possible new medications are, they also raise questions about affordability and accessibility. Innovative drug treatments involving gene ...
The American Society of Health-System Pharmacists (ASHP) reported that 323 "active medication shortages" were reported in January–March 2024. As a result of drug scarcity, many healthcare systems were forced to either ration out essential drugs, triage patients based on the severity of their condition and their need for the drug, or both.
In February 2024, the US Food and Drug Administration (FDA) added an indication for immunoglobulin E-mediated food allergy for the reduction of allergic reactions, including anaphylaxis, which may occur with accidental exposure to one or more foods. [12] Omalizumab can be used as a monotherapy or in combination with oral immunotherapy. [21]
Viatris was formed with the merger of Mylan and Pfizer's Upjohn business and has generic and key branded drugs in its portfolio, including erectile dysfunction drug Viagra, anti-anxiety medication ...
Proprietary drug are chemicals used for medicinal purposes which are formulated or manufactured under a name protected from competition through trademark or patent. [1] The invented drug is usually still considered proprietary even if the patent expired. [2] When a patent expires, generic drugs may be developed and
The Government Delegation for the National Plan on Drugs (Spanish: Delegación del Gobierno para el Plan Nacional sobre Drogas, DGPNSD) is the executive body of the Spanish Ministry of Health, attached to the Secretary of State for Health, which is responsible for the management, promotion, general coordination and supervision of the services in charge of updating and executing the National ...